AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37945305 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Fit intervention (multimodal and personalised EF intervention) consisting of computer-based EF training using CogniFit Inc 2022, performed three times a week at home; weekly EF remote strategy coaching and analogue games.
Number of subjects: 40
Study 37945305 — intervention group
Group type: COMPARATOR
Intervention: Control group following their daily routines and completing a diary about their everyday activities four times a week.
Number of subjects: 40
Study 37945314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough seconds as the unit of analysis
Number of subjects: 24
Study 37945314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralabeller agreement
Number of subjects: 24
Study 37945314 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlabeller agreement
Number of subjects: 24
Study 37945314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough sound length and epoch size
Number of subjects: 24
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: ED clinician AAS likelihood rating
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Dissection Detection Risk Score (ADD-RS)
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: AORTAs
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian clinical decision tool
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheffield clinical decision tool
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: CT aorta angiogram (CTA)
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed AAS diagnosis
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS considered possible by ED clinician
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS considered most likely by ED clinician
Number of subjects: 5548
Study 37945311 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS considered not possible by ED clinician
Number of subjects: 5548
Study 37945326 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCS) followed by non-platinum single agent chemotherapy (paclitaxel, gemcitabine or liposomal adriamycin) for at least 4 cycles
Number of subjects: 140
Study 37945326 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum single agent chemotherapy
Number of subjects: 140
Study 37945413 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (target effect-site concentrations of 0.5, 1, 2, 3, 4 ng/ml)
Number of subjects: 74
Study 37945413 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 74
Study 37945419 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist-led educational intervention and medication review
Number of subjects: 158
Study 37945419 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 158
Study 37945441 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 300
Study 37945441 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 300
Study 37945671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent feeding (6x/day)
Number of subjects: 75
Study 37945671 — intervention group
Group type: COMPARATOR
Intervention: Continuous feeding (control arm)
Number of subjects: 75
Study 37945748 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab (bev) + olaparib (ola)
Number of subjects: 449
Study 37945755 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone with daratumumab
Number of subjects: 0
Study 37946117 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotoxic chemotherapy
Number of subjects: 200
Study 37946117 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective assessments (biothesiometry, tuning fork, monofilament tests, Timed-Up-and-Go tests, handgrip dynamometry, 5-time repeated chair stand test)
Number of subjects: 200
Study 37946117 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices measuring daily gait quality and physical activity
Number of subjects: 200
Study 37946117 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly electronic surveys for self-reporting symptoms
Number of subjects: 200
Study 37946122 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high intensity resistance training and aerobic training (n=44)
Number of subjects: 87
Study 37946122 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training alone (n=43)
Number of subjects: 87
Study 37946125 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-based CT organ feature
Number of subjects: 208
Study 37946136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy (SBRT)
Number of subjects: 0
Study 37946136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atezolizumab, tiragolumab, and SBRT
Number of subjects: 0
Study 37946132 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component implementation strategies including facilitation, audit and feedback, and learning collaboratives.
Number of subjects: 26
Study 37946132 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 26
Study 37946167 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant intestinal microbiota characterized by 16S and metagenomic sequencing
Number of subjects: 250
Study 37946167 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk composition
Number of subjects: 250
Study 37946167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and environment impact
Number of subjects: 250
Study 37946167 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal microbiome transfer
Number of subjects: 250
Study 37946167 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of microbiota and maternal milk
Number of subjects: 250
Study 37946167 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-developmental outcomes and behavior
Number of subjects: 250
Study 37946190 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR + Mindfulness
Number of subjects: 100
Study 37946190 — intervention group
Group type: COMPARATOR
Intervention: Relaxation intervention
Number of subjects: 100
Study 37946201 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-treatment decreases in peak PE from imaging
Number of subjects: 35
Study 37946201 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment decreases in several DCE-MRI measures
Number of subjects: 35
Study 37946233 — intervention group
Group type: EXPERIMENTAL
Intervention: OEND intervention
Number of subjects: 29
Study 37946235 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Replicating Effective Programs (REP)
Number of subjects: 8
Study 37946235 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation activities including training and implementation facilitation
Number of subjects: 8
Study 37946235 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention
Number of subjects: 8
Study 37946235 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 8
Study 37946256 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients with ATTR amyloidosis
Number of subjects: 6135
Study 37946256 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic gene carriers
Number of subjects: 6135
Study 37946262 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 21
Study 37946272 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear protein powder shake (200 ml containing 20 g of whey protein) taken daily for the first 6 months after LRYGB.
Number of subjects: 0
Study 37946272 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric clear placebo shake containing maltodextrin.
Number of subjects: 0
Study 37946283 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2)
Number of subjects: 43
Study 37946283 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) with nivolumab (3 mg/kg)
Number of subjects: 43
Study 37946291 — intervention group
Group type: EXPERIMENTAL
Intervention: RxWell™ plus usual care (intervention group)
Number of subjects: 0
Study 37946291 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 37946302 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep shotgun metagenomic sequencing
Number of subjects: 215
Study 37946314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment, one or two sessions
Number of subjects: 85
Study 37946314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 85
Study 37946522 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional stenting strategy
Number of subjects: 200
Study 37946522 — intervention group
Group type: COMPARATOR
Intervention: Systematic culotte stenting
Number of subjects: 200
Study 37947096 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC (cystatin C) measured 1 to 3 days after delivery
Number of subjects: 566
Study 37947096 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC >75th percentile and preeclampsia
Number of subjects: 566
Study 37947096 — intervention group
Group type: COMPARATOR
Intervention: CysC ≤75th percentile and no preeclampsia
Number of subjects: 566
Study 37947096 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC only or preeclampsia only
Number of subjects: 566
Study 37947096 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC and preterm delivery
Number of subjects: 566
Study 37947105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine/abacavir
Number of subjects: 37
Study 37947105 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-abacavir regimen (bictegravir/emtricitabine/TAF)
Number of subjects: 37
Study 37947105 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-HIV)
Number of subjects: 37
Study 37947105 — intervention group
Group type: EXPERIMENTAL
Intervention: People with HIV (PWH)
Number of subjects: 37
Study 37947140 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 699
Study 37947157 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 150 mg weekly (escalation to 200 mg allowed)
Number of subjects: 16
Study 37947157 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206
Number of subjects: 16
Study 37947177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin testing
Number of subjects: 0
Study 37947190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) 1.3 mg/m2 body surface area subcutaneously once weekly for 8 weeks followed by oral cyclophosphamide 1 mg/kg/d for 4 months
Number of subjects: 5
Study 37947190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ)
Number of subjects: 5
Study 37947190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) followed by cyclophosphamide
Number of subjects: 5
Study 37947276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry products
Number of subjects: 8857
Study 37947315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active GPA patients
Number of subjects: 72
Study 37947315 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72
Study 37947315 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA patients with kidney involvement
Number of subjects: 72
Study 37947315 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA patients in remission
Number of subjects: 72
Study 37947315 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA patients
Number of subjects: 72
Study 37947366 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Number of subjects: 125
Study 37947366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 37947407 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS CLT
Number of subjects: 10
Study 37947583 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation (NESA device)
Number of subjects: 30
Study 37947583 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 30
Study 37947583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 37947856 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (imVR) rehabilitation + conventional rehabilitation
Number of subjects: 40
Study 37947856 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation only
Number of subjects: 40
Study 37947905 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 15
Study 37947905 — intervention group
Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 15
Study 37947974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB) after neoadjuvant systemic treatment (NAST)
Number of subjects: 237
Study 37947974 — intervention group
Group type: COMPARATOR
Intervention: Routine imaging after NAST
Number of subjects: 237
Study 37947974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB)
Number of subjects: 237
Study 37947987 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-GOG-Ntx (self-report measure for CIPN)
Number of subjects: 306
Study 37947987 — intervention group
Group type: COMPARATOR
Intervention: Clinical grading of CIPN by providers using the Balis Pediatric Neuropathy Scale
Number of subjects: 306
Study 37947987 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL) measure
Number of subjects: 306
Study 37947987 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-GOG-Ntx
Number of subjects: 306
Study 37948006 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg SC per month (after a 240 mg loading dose)
Number of subjects: 580
Study 37948006 — intervention group
Group type: COMPARATOR
Intervention: Rimegepant 75 mg ODT q.o.d.
Number of subjects: 580
Study 37948006 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 580
Study 37948006 — intervention group
Group type: COMPARATOR
Intervention: Rimegepant
Number of subjects: 580
Study 37948075 — intervention group
Group type: EXPERIMENTAL
Intervention: ED initiation of buprenorphine (intervention group)
Number of subjects: 1026
Study 37948075 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support intervention (intervention group)
Number of subjects: 1026
Study 37948075 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 1026
Study 37948081 — intervention group
Group type: EXPERIMENTAL
Intervention: A-ICU intervention
Number of subjects: 159
Study 37948081 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 159
Study 37948113 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game (VR)
Number of subjects: 20
Study 37948113 — intervention group
Group type: COMPARATOR
Intervention: Standard care using a wall TV (Control)
Number of subjects: 20
Study 37948170 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISCA (patient-centered approach including healthy lifestyle promotion, pharmacological management of CVRFs, psychotropic drug optimization, and motivational follow-up)
Number of subjects: 46
Study 37948170 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISCA
Number of subjects: 46
Study 37948170 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 46
Study 37948425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound diagnostic tool
Number of subjects: 438
Study 37948425 — intervention group
Group type: COMPARATOR
Intervention: Neurophysiological test (NPT)
Number of subjects: 438
Study 37948612 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity (PA) intervention
Number of subjects: 1377
Study 37948612 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging (HA) intervention
Number of subjects: 1377
Study 37948612 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity (PA)
Number of subjects: 1377
Study 37948704 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Number of subjects: 0
Study 37948704 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37948736 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Molgramostim
Number of subjects: 0
Study 37948759 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing monoclonal antibodies (nmAbs)
Number of subjects: 2149
Study 37948759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2149
Study 37948791 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 6-minute walk distance (6MWD)
Number of subjects: 184
Study 37948832 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-6356 3 mg/day
Number of subjects: 168
Study 37948832 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-6356 6 mg/day
Number of subjects: 168
Study 37948832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 37949090 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg)
Number of subjects: 726
Study 37949090 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (200 μg/kg bodyweight)
Number of subjects: 726
Study 37949165 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS (ESR iGuide) with active decision support
Number of subjects: 32
Study 37949165 — intervention group
Group type: COMPARATOR
Intervention: CDSS (ESR iGuide) without active decision support (control condition)
Number of subjects: 32
Study 37949351 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 952
Study 37949351 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 952
Study 37949351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 952
Study 37949351 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg and 100 mg
Number of subjects: 952
Study 37949432 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month pragmatic multidomain intervention
Number of subjects: 398
Study 37949481 — intervention group
Group type: EXPERIMENTAL
Intervention: cSS+CMB+
Number of subjects: 673
Study 37949481 — intervention group
Group type: EXPERIMENTAL
Intervention: CMB in cSS- patients
Number of subjects: 673
Study 37949481 — intervention group
Group type: EXPERIMENTAL
Intervention: CMB in context of cSS+
Number of subjects: 673
Study 37949481 — intervention group
Group type: COMPARATOR
Intervention: cSS-CMB-
Number of subjects: 673
Study 37949481 — intervention group
Group type: COMPARATOR
Intervention: cSS-CMB+
Number of subjects: 673
Study 37949481 — intervention group
Group type: COMPARATOR
Intervention: cSS+CMB-
Number of subjects: 673
Study 37949595 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 58
Study 37949595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming (Kinect Adventures)
Number of subjects: 58
Study 37949595 — intervention group
Group type: COMPARATOR
Intervention: Functional training
Number of subjects: 58
Study 37949617 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL treatment during chemotherapy without IFNa (n=13)
Number of subjects: 16
Study 37949617 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 16
Study 37949617 — intervention group
Group type: COMPARATOR
Intervention: TIL treatment with IFNa
Number of subjects: 16
Study 37949617 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL therapy
Number of subjects: 16
Study 37949617 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL infusions during platinum-based chemotherapy
Number of subjects: 16
Study 37949619 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetrics and gynaecology (O&G) trainees
Number of subjects: 47
Study 37949619 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior obstetrics and gynaecology (O&G) trainees
Number of subjects: 47
Study 37949621 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg oral daily
Number of subjects: 0
Study 37949621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37949622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathrombus thrombolysis with a pierced balloon
Number of subjects: 2500
Study 37949622 — intervention group
Group type: COMPARATOR
Intervention: Upfront routine manual aspiration thrombectomy
Number of subjects: 2500
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: 32.5 Gy in five fractions
Number of subjects: 136
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 Gy in five fractions
Number of subjects: 136
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 Gy in five fractions
Number of subjects: 136
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy in five fractions
Number of subjects: 136
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher radiation dose (37.5-40 Gy)
Number of subjects: 136
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable intermediate risk
Number of subjects: 136
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses (32.5 to 40 Gy)
Number of subjects: 136
Study 37949730 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose levels
Number of subjects: 136
Study 37949923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) of S1
Number of subjects: 3
Study 37949923 — intervention group
Group type: COMPARATOR
Intervention: Biomimetic stimulation
Number of subjects: 3
Study 37949931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for visual impairment
Number of subjects: 120
Study 37949931 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment at diagnosis
Number of subjects: 120
Study 37949931 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 120
Study 37950144 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil (70 mg)
Number of subjects: 184
Study 37950144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184